The Delta and Omicron variants of SARS-CoV-2: what we know so far
The world has not yet completely overcome the fear of the havoc brought by SARS-CoV-2.
The virus has undergone several mutations since its initial appearance in China in …
The virus has undergone several mutations since its initial appearance in China in …
Mechanistic insights into the immune pathophysiology of COVID-19; an in-depth review
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which causes
coronavirus-19 (COVID-19), has caused significant morbidity and mortality globally. In …
coronavirus-19 (COVID-19), has caused significant morbidity and mortality globally. In …
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance
JM Strizki, JM Gaspar, JA Howe… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Molnupiravir, an oral prodrug of N-hydroxycytidine (NHC), previously demonstrated broad in
vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the …
vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the …
Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
Continued emergence of SARS-CoV-2 variants of concern that are capable of escaping
vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics …
vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics …
Prevalence of medical contraindications to nirmatrelvir/ritonavir in a cohort of hospitalized and nonhospitalized patients with COVID-19
S Lim, CJ Tignanelli, N Hoertel… - Open Forum …, 2022 - academic.oup.com
This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among
66 007 patients with coronavirus disease 2019 in a large health care system. A possible …
66 007 patients with coronavirus disease 2019 in a large health care system. A possible …
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged,
causing a global pandemic called COVID-19. Currently, there is no definitive treatment for …
causing a global pandemic called COVID-19. Currently, there is no definitive treatment for …
Demographic and clinical factors associated with reactivity of anti-SARS-CoV-2 antibodies in serbian convalescent plasma donors
J Grujić, N Bujandrić, Z Budakov-Obradović… - International Journal of …, 2021 - mdpi.com
Passive immunotherapy with convalescent COVID-19 plasma (CCP) is used as a
therapeutic procedure in many countries, including Serbia. In this study, we analyzed the …
therapeutic procedure in many countries, including Serbia. In this study, we analyzed the …
Circulating Dynamics of SARS‐CoV‐2 Variants between April 2021 and February 2022 in Turkey
The diagnosis of new variants and monitoring their potential effects on diagnosis,
therapeutics, and vaccines by genomic sequencing is essential to manage global public …
therapeutics, and vaccines by genomic sequencing is essential to manage global public …
Understanding COVID-19 vaccines today: Are T-cells key players?
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has heavily mutated since
the beginning of the coronavirus-2019 (COVID-19) pandemic. In this regard, the so-called …
the beginning of the coronavirus-2019 (COVID-19) pandemic. In this regard, the so-called …
Molecular and clinical epidemiology of SARS-CoV-2 infection among vaccinated and unvaccinated individuals in a large healthcare organization from New Jersey
JR Mediavilla, T Lozy, A Lee, J Kim, VW Kan, E Titova… - Viruses, 2023 - mdpi.com
New Jersey was among the first states impacted by the COVID-19 pandemic, with one of the
highest overall death rates in the nation. Nevertheless, relatively few reports have been …
highest overall death rates in the nation. Nevertheless, relatively few reports have been …